NO2928881T3 - - Google Patents

Info

Publication number
NO2928881T3
NO2928881T3 NO13799520A NO13799520A NO2928881T3 NO 2928881 T3 NO2928881 T3 NO 2928881T3 NO 13799520 A NO13799520 A NO 13799520A NO 13799520 A NO13799520 A NO 13799520A NO 2928881 T3 NO2928881 T3 NO 2928881T3
Authority
NO
Norway
Application number
NO13799520A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2928881T3 publication Critical patent/NO2928881T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO13799520A 2012-12-07 2013-12-02 NO2928881T3 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12196022 2012-12-07
PCT/EP2013/075225 WO2014086705A1 (en) 2012-12-07 2013-12-02 Novel pyridine derivatives
EP13799520.5A EP2928881B1 (en) 2012-12-07 2013-12-02 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
NO2928881T3 true NO2928881T3 (enExample) 2018-08-11

Family

ID=47290804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13799520A NO2928881T3 (enExample) 2012-12-07 2013-12-02

Country Status (33)

Country Link
US (1) US9522886B2 (enExample)
EP (2) EP2928881B1 (enExample)
JP (1) JP6426618B2 (enExample)
KR (1) KR20150092282A (enExample)
CN (2) CN104837831B (enExample)
AR (1) AR093843A1 (enExample)
AU (2) AU2013354278B2 (enExample)
BR (1) BR112015012919A2 (enExample)
CA (1) CA2890100A1 (enExample)
CL (1) CL2015001536A1 (enExample)
CO (1) CO7350620A2 (enExample)
CR (1) CR20150250A (enExample)
DK (1) DK2928881T3 (enExample)
EA (1) EA026669B1 (enExample)
ES (1) ES2668690T3 (enExample)
HR (1) HRP20180672T1 (enExample)
HU (1) HUE036911T2 (enExample)
IL (1) IL239075B (enExample)
LT (1) LT2928881T (enExample)
MA (1) MA38239A1 (enExample)
MX (1) MX2015007155A (enExample)
NO (1) NO2928881T3 (enExample)
PE (1) PE20151025A1 (enExample)
PH (1) PH12015501083B1 (enExample)
PL (1) PL2928881T3 (enExample)
PT (1) PT2928881T (enExample)
RS (1) RS57143B1 (enExample)
SG (2) SG10201800170YA (enExample)
SI (1) SI2928881T1 (enExample)
TW (1) TWI600645B (enExample)
UA (1) UA114656C2 (enExample)
WO (1) WO2014086705A1 (enExample)
ZA (1) ZA201503969B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143220B (zh) 2013-03-07 2018-06-22 豪夫迈·罗氏有限公司 吡唑衍生物
PE20151559A1 (es) 2013-03-26 2015-11-05 Hoffmann La Roche Nuevos derivados de piridina
HRP20181141T1 (hr) 2013-05-02 2018-09-21 F. Hoffmann - La Roche Ag Derivati purina kao agonisti cb2 receptora
BR112015027394A8 (pt) 2013-05-02 2018-01-30 Hoffmann La Roche derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
AU2014317229B2 (en) 2013-09-06 2018-11-08 F. Hoffmann-La Roche Ag Novel triazolo(4,5-d)pyrimidine derivatives
AU2015239537B2 (en) * 2014-04-04 2019-04-04 Eidgenoessische Technische Hochschule Zuerich 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2017097732A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Phenyl derivatives as cannabinoid receptor 2 agonists
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
AR112199A1 (es) 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
JP2021521228A (ja) * 2018-04-18 2021-08-26 ビーエイエスエフ・ソシエタス・エウロパエアBasf Se D−グルカロ−6,3−ラクトンモノエステル及びその製造方法
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
EP3814337B1 (en) * 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
MX2020012760A (es) 2018-06-27 2021-03-25 Hoffmann La Roche Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
EP3814328B1 (en) * 2018-06-27 2026-03-11 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2
CN114502538A (zh) * 2019-09-30 2022-05-13 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
EP4326257A4 (en) * 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008040649A2 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
EA201591064A1 (ru) 2015-09-30
EP2928881B1 (en) 2018-03-14
MX2015007155A (es) 2015-10-14
AU2017279648A1 (en) 2018-01-18
CN107674061A (zh) 2018-02-09
ZA201503969B (en) 2016-04-28
US9522886B2 (en) 2016-12-20
SI2928881T1 (en) 2018-07-31
AR093843A1 (es) 2015-06-24
CN104837831A (zh) 2015-08-12
TW201427951A (zh) 2014-07-16
IL239075B (en) 2018-11-29
HUE036911T2 (hu) 2018-08-28
CO7350620A2 (es) 2015-08-10
EP2928881A1 (en) 2015-10-14
HK1208031A1 (en) 2016-02-19
LT2928881T (lt) 2018-06-11
WO2014086705A1 (en) 2014-06-12
AU2013354278B2 (en) 2017-10-12
MA38239A1 (fr) 2017-03-31
TWI600645B (zh) 2017-10-01
EP3357918A1 (en) 2018-08-08
AU2013354278A1 (en) 2015-05-14
CL2015001536A1 (es) 2015-10-23
US20150307452A1 (en) 2015-10-29
PH12015501083A1 (en) 2015-08-03
SG11201504416XA (en) 2015-07-30
RS57143B1 (sr) 2018-07-31
HRP20180672T1 (hr) 2018-06-01
CN104837831B (zh) 2017-10-31
PE20151025A1 (es) 2015-07-15
PT2928881T (pt) 2018-05-07
ES2668690T3 (es) 2018-05-21
BR112015012919A2 (pt) 2017-07-11
CR20150250A (es) 2015-06-11
UA114656C2 (uk) 2017-07-10
JP2016501240A (ja) 2016-01-18
PH12015501083B1 (en) 2015-08-03
CA2890100A1 (en) 2014-06-12
KR20150092282A (ko) 2015-08-12
SG10201800170YA (en) 2018-02-27
IL239075A0 (en) 2015-07-30
EA026669B1 (ru) 2017-05-31
DK2928881T3 (en) 2018-05-28
JP6426618B2 (ja) 2018-11-21
PL2928881T3 (pl) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112014024841A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017607A2 (enExample)
BR112014017592A2 (enExample)
BR112014017646A2 (enExample)
AR092201A1 (enExample)
BR112013027865A2 (enExample)
BR112014017644A2 (enExample)
BR112014017634A2 (enExample)
BR112014017588A2 (enExample)
BR112014017647A2 (enExample)
BR112014017618A2 (enExample)
BR112014017627A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014019730A2 (enExample)
BR112014017630A2 (enExample)
BR112014017641A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)
BR112014017671A2 (enExample)
BR112014017589A2 (enExample)
BR112014017636A2 (enExample)
BR112014017593A2 (enExample)